Baseline characteristics for the entire cohort
| Characteristic . | Entire group (N = 357) . |
|---|---|
| Age, y, median (range) | 70 (19-94) |
| Sex, n (%) | |
| Female | 126 (36) |
| Male | 231 (63.9) |
| Body mass index, median (range) | 26.9 (16.8-60.2) |
| Smoking history, n (%) | |
| Current | 18 (5.0) |
| Former | 142 (39.8) |
| Never | 173 (48.5) |
| Unknown | 24 (6.7) |
| ECOG performance status score, n (%) | |
| 0 | 120 (33.6) |
| 1 | 156 (43.8) |
| 2 | 30 (8.4) |
| 3 | 3 (0.8) |
| Missing | 48 (13.5) |
| Laboratory values, median (IQR) | |
| Hb, g/dL, median (IQR) | 11 (9.4-12.7) |
| Patients with Hb of <10 g/dL; n (%) | 120 (33.6) |
| Mean corpuscular volume, fL, median (range) | 95.4 (90-102.4) |
| PLT, ×109/L, median (IQR) | 121 (78-198) |
| Patients with PLTs of <100 × 109/L, n (%) | 133 (37.3) |
| WBCs, ×109/L, median (IQR) | 3.60 (2.60-5.54) |
| ANC, ×109/L, median (IQR) | 1.91 (1.10-3.30) |
| Patients with ANC of <1 × 109/L, n (%) | 25 (7.0) |
| AMC, ×109/L, median (IQR) | 0.4 (0.28-0.57) |
| Patients with CCMUS, n (%) | 97 (27.2) |
| Total no. of mutational variants | 592 |
| VAF, median (range) | 31.7% (3%-99.7%) |
| Mutations per patient, n (%) | |
| 0 | 39 (10.9) |
| 1 | 156 (43.7) |
| 2 | 86 (24.1) |
| >2 | 76 (21.3) |
| Median no. of mutations | 1 |
| Patients with cytogenetic abnormalities, n (%) | 79 (22.1) |
| Characteristic . | Entire group (N = 357) . |
|---|---|
| Age, y, median (range) | 70 (19-94) |
| Sex, n (%) | |
| Female | 126 (36) |
| Male | 231 (63.9) |
| Body mass index, median (range) | 26.9 (16.8-60.2) |
| Smoking history, n (%) | |
| Current | 18 (5.0) |
| Former | 142 (39.8) |
| Never | 173 (48.5) |
| Unknown | 24 (6.7) |
| ECOG performance status score, n (%) | |
| 0 | 120 (33.6) |
| 1 | 156 (43.8) |
| 2 | 30 (8.4) |
| 3 | 3 (0.8) |
| Missing | 48 (13.5) |
| Laboratory values, median (IQR) | |
| Hb, g/dL, median (IQR) | 11 (9.4-12.7) |
| Patients with Hb of <10 g/dL; n (%) | 120 (33.6) |
| Mean corpuscular volume, fL, median (range) | 95.4 (90-102.4) |
| PLT, ×109/L, median (IQR) | 121 (78-198) |
| Patients with PLTs of <100 × 109/L, n (%) | 133 (37.3) |
| WBCs, ×109/L, median (IQR) | 3.60 (2.60-5.54) |
| ANC, ×109/L, median (IQR) | 1.91 (1.10-3.30) |
| Patients with ANC of <1 × 109/L, n (%) | 25 (7.0) |
| AMC, ×109/L, median (IQR) | 0.4 (0.28-0.57) |
| Patients with CCMUS, n (%) | 97 (27.2) |
| Total no. of mutational variants | 592 |
| VAF, median (range) | 31.7% (3%-99.7%) |
| Mutations per patient, n (%) | |
| 0 | 39 (10.9) |
| 1 | 156 (43.7) |
| 2 | 86 (24.1) |
| >2 | 76 (21.3) |
| Median no. of mutations | 1 |
| Patients with cytogenetic abnormalities, n (%) | 79 (22.1) |
ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range.